vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and Essent Group Ltd. (ESNT). Click either name above to swap in a different company.
Essent Group Ltd. is the larger business by last-quarter revenue ($312.4M vs $196.0M, roughly 1.6× Axsome Therapeutics, Inc.). Essent Group Ltd. runs the higher net margin — 49.6% vs -14.6%, a 64.2% gap on every dollar of revenue. On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (65.0% vs -0.8%). Essent Group Ltd. produced more free cash flow last quarter ($848.7M vs $-18.7M). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs 2.3%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Essentra PLC is a supplier of plastic and fibre products. The company operates internationally from headquarters in Kidlington, Oxfordshire. It is listed on the London Stock Exchange.
AXSM vs ESNT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $196.0M | $312.4M |
| Net Profit | $-28.6M | $155.0M |
| Gross Margin | — | — |
| Operating Margin | -13.8% | 59.1% |
| Net Margin | -14.6% | 49.6% |
| Revenue YoY | 65.0% | -0.8% |
| Net Profit YoY | 61.9% | -7.7% |
| EPS (diluted) | $-0.55 | $1.61 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $196.0M | $312.4M | ||
| Q3 25 | $171.0M | $311.8M | ||
| Q2 25 | $150.0M | $319.1M | ||
| Q1 25 | $121.5M | $317.6M | ||
| Q4 24 | $118.8M | $315.0M | ||
| Q3 24 | $104.8M | $316.6M | ||
| Q2 24 | $87.2M | $312.9M | ||
| Q1 24 | $75.0M | $298.4M |
| Q4 25 | $-28.6M | $155.0M | ||
| Q3 25 | $-47.2M | $164.2M | ||
| Q2 25 | $-48.0M | $195.3M | ||
| Q1 25 | $-59.4M | $175.4M | ||
| Q4 24 | $-74.9M | $167.9M | ||
| Q3 24 | $-64.6M | $176.2M | ||
| Q2 24 | $-79.3M | $203.6M | ||
| Q1 24 | $-68.4M | $181.7M |
| Q4 25 | -13.8% | 59.1% | ||
| Q3 25 | -27.0% | 63.9% | ||
| Q2 25 | -24.5% | 72.4% | ||
| Q1 25 | -46.9% | 65.2% | ||
| Q4 24 | -61.1% | 61.9% | ||
| Q3 24 | -59.8% | 65.6% | ||
| Q2 24 | -89.5% | 76.4% | ||
| Q1 24 | -89.7% | 71.6% |
| Q4 25 | -14.6% | 49.6% | ||
| Q3 25 | -27.6% | 52.7% | ||
| Q2 25 | -32.0% | 61.2% | ||
| Q1 25 | -48.9% | 55.2% | ||
| Q4 24 | -63.1% | 53.3% | ||
| Q3 24 | -61.7% | 55.6% | ||
| Q2 24 | -91.0% | 65.1% | ||
| Q1 24 | -91.1% | 60.9% |
| Q4 25 | $-0.55 | $1.61 | ||
| Q3 25 | $-0.94 | $1.67 | ||
| Q2 25 | $-0.97 | $1.93 | ||
| Q1 25 | $-1.22 | $1.69 | ||
| Q4 24 | $-1.54 | $1.59 | ||
| Q3 24 | $-1.34 | $1.65 | ||
| Q2 24 | $-1.67 | $1.91 | ||
| Q1 24 | $-1.44 | $1.70 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $322.9M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $88.3M | $5.8B |
| Total Assets | $689.8M | $7.4B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $322.9M | — | ||
| Q3 25 | $325.3M | — | ||
| Q2 25 | $303.0M | — | ||
| Q1 25 | $300.9M | — | ||
| Q4 24 | $315.4M | — | ||
| Q3 24 | $327.3M | — | ||
| Q2 24 | $315.7M | — | ||
| Q1 24 | $331.4M | — |
| Q4 25 | $88.3M | $5.8B | ||
| Q3 25 | $73.7M | $5.7B | ||
| Q2 25 | $73.1M | $5.7B | ||
| Q1 25 | $53.2M | $5.7B | ||
| Q4 24 | $57.0M | $5.6B | ||
| Q3 24 | $92.9M | $5.6B | ||
| Q2 24 | $102.9M | $5.4B | ||
| Q1 24 | $144.0M | $5.2B |
| Q4 25 | $689.8M | $7.4B | ||
| Q3 25 | $669.3M | $7.4B | ||
| Q2 25 | $639.8M | $7.2B | ||
| Q1 25 | $596.7M | $7.2B | ||
| Q4 24 | $568.5M | $7.1B | ||
| Q3 24 | $561.5M | $7.1B | ||
| Q2 24 | $548.2M | $6.7B | ||
| Q1 24 | $545.7M | $6.6B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.7M | $856.1M |
| Free Cash FlowOCF − Capex | $-18.7M | $848.7M |
| FCF MarginFCF / Revenue | -9.6% | 271.7% |
| Capex IntensityCapex / Revenue | 0.0% | 2.4% |
| Cash ConversionOCF / Net Profit | — | 5.52× |
| TTM Free Cash FlowTrailing 4 quarters | $-93.9M | $1.5B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-18.7M | $856.1M | ||
| Q3 25 | $1.0M | $215.9M | ||
| Q2 25 | $-32.4M | $189.5M | ||
| Q1 25 | $-43.4M | $221.6M | ||
| Q4 24 | $-26.2M | $861.5M | ||
| Q3 24 | $-18.6M | $229.2M | ||
| Q2 24 | $-30.1M | $188.7M | ||
| Q1 24 | $-53.5M | $216.9M |
| Q4 25 | $-18.7M | $848.7M | ||
| Q3 25 | $988.0K | $210.6M | ||
| Q2 25 | $-32.4M | $188.8M | ||
| Q1 25 | $-43.7M | $221.3M | ||
| Q4 24 | $-26.2M | $854.8M | ||
| Q3 24 | $-18.7M | $228.7M | ||
| Q2 24 | $-30.2M | $187.6M | ||
| Q1 24 | $-53.6M | $212.5M |
| Q4 25 | -9.6% | 271.7% | ||
| Q3 25 | 0.6% | 67.5% | ||
| Q2 25 | -21.6% | 59.2% | ||
| Q1 25 | -36.0% | 69.7% | ||
| Q4 24 | -22.1% | 271.3% | ||
| Q3 24 | -17.9% | 72.2% | ||
| Q2 24 | -34.6% | 60.0% | ||
| Q1 24 | -71.4% | 71.2% |
| Q4 25 | 0.0% | 2.4% | ||
| Q3 25 | 0.0% | 1.7% | ||
| Q2 25 | 0.0% | 0.2% | ||
| Q1 25 | 0.3% | 0.1% | ||
| Q4 24 | 0.0% | 2.1% | ||
| Q3 24 | 0.1% | 0.2% | ||
| Q2 24 | 0.1% | 0.3% | ||
| Q1 24 | 0.1% | 1.5% |
| Q4 25 | — | 5.52× | ||
| Q3 25 | — | 1.31× | ||
| Q2 25 | — | 0.97× | ||
| Q1 25 | — | 1.26× | ||
| Q4 24 | — | 5.13× | ||
| Q3 24 | — | 1.30× | ||
| Q2 24 | — | 0.93× | ||
| Q1 24 | — | 1.19× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXSM
Segment breakdown not available.
ESNT
| Mortgage Insurance Segment | $192.4M | 62% |
| Other | $120.0M | 38% |
